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Abstract. In this work alternative methods for the production of terbium isotopes, and in
particular 152Tb and 155Tb, have been investigated. These isotopes, which could be used for
theragnostics, have been produced using an alpha and a proton beam incident on europium
and gadolinium targets, respectively. The experimental results have been compared with the
predicted cross-sections, calculated using TALYS and PACE4 code.
1. Introduction
Over time the diagnosis and treatment tools used to identify and remove cancer growths in
patients have evolved. New ideas and techniques are continuously being investigated to improve
the treatment of cancer. Table 1 lists some of the currently employed techniques to diagnose
and treat cancer.
Table 1. Currently used techniques to treat and diagnose cancer.
Treatment Diagnostic Imaging
Surgery X-ray
Internal and External Radiation therapy CT (Computerised Tomography)
Chemotherapy MRI (Magnetic resonance imaging)
Immunotherapy PET (Positron Emission Tomography)
Hormone therapy
Gamma Camera/SPECT
(Single Photon Emission Computed Tomography)
Stem cell transplant Ultrasound
Targeted therapy Mammography
Internal radiotherapy, PET (Positron Emission Tomography) and SPECT (Single Photon
Emission Computed Tomography) imaging are techniques classified under ‘Nuclear medicine’.
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Nuclear medicine works by introducing radioactive isotopes into the body and using the different
forms of decay to either perform therapy or diagnostic imaging of a patient.
Therapy can be performed by using either beta or alpha emitting isotopes. The beta or
alpha particles ionise the neighbouring cells causing damage to the DNA, often leading to either
single- or double-strand breakages, respectively. Positron emitting isotopes are used to perform
diagnostic PET imaging and isotopes which predominantly emit gammas are used for diagnostic
SPECT imaging.
In nuclear medicine, cancer cells are located by attaching the radioactive nuclide to a
biological targeting agent. For example, a glucose molecule can be replicated and modified
such that a 18F atom is attached to form FDG (fluorodeoxyglucose), see figure 1 . In this case
the biological targeting agent reacts in the body as glucose does. Glucose is drawn into cells
which are using up energy in metabolic processes i.e. the cells will break-down the glucose
molecule to release energy for the cell’s use. FDG will behave in the same way as glucose and
will thus concentrate in areas of high activity, e.g. active areas of the brain and cancer lesions.
It is the higher concentration of FDG in these areas which will be highlighted in a PET and
SPECT images.
Figure 1. Molecular diagrams of Glucose and FDG (fluorodeoxyglucose)
A more specific method of cancer targeting is to use proteins (peptides). Cancer cells will
have specifically shaped proteins on their outer membranes. If a complementary (i.e. fits like
a glove over a hand) peptide is made, this will only attach to that specific cancer protein. A
radioactive nuclide can then be attached to this complementary peptide using a chelator (linker)
as shown in figure 2. This can be a more direct and tailored method of targeting cancer lesions.
Figure 2. Schematic diagram of a radioactive nuclide attached to a peptide targeting molecule
It is the combination of therapy and diagnostic imaging (theragnostics) which aims to
provide a more tailored treatment to cancer. By monitoring therapy with diagnostic imaging the
effectiveness of the treatment can be seen and changed according to need. The radiation dose
received by a patient during treatment can also be monitored. Currently, a combination of Lu
and Ga is commonly used in hospitals for β−therapy and PET diagnostic imaging, respectively.
These nuclei are different elements, hence, they will not necessarily chemically interact the same
within the body. This provides uncertainty in the comparing diagnostic imaging to therapy,
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which in turn provides doubt to the reliability of a theragnostic treatment. A way of resolving
this issue would be to use different isotopes of the same element to perform the therapy and
diagnostic imaging. Scandium, copper, arsenic and terbium are a few examples of proposed
elements which have suitable properties for medical use. Some of the main properties to consider
are half-life and energy of emitted radiation. The half-life of a medical isotope must be of
reasonable length, so that it can be produced, transported, undergo radiochemical procedures
and pass regulation tests before being administered to the patient. There must then be enough
activity for the treatment or diagnostic imaging to be carried out effectively. However, the
half-life must also be short enough that the isotope is not providing an unnecessarily large dose
to the patient and their surroundings. In addition to the half-life requirements, the energies
of the emitted radiation must also be suitable for the task. For example, a SPECT isotopes
would ideally only emit gammas of a low energy (100-200 keV) which lie within a region of
high efficiency for the gamma detectors; ideal PET isotopes would emit solely positrons and no
gamma-rays other than 511 keV gammas from positron annihilation. In addition to this, for
isotopes to be practical for hospital use, they should be able to be produced locally if not within
the hospital. Hospital cyclotrons predominantly accelerate proton beams up to 17 MeV. This
limits the type of isotopes that can be produced and is important to consider when developing
new production methods.
Production of terbium by ISOLDE (Isotope Separator On Line DEtector) and MEDICIS
(Medical Isotopes Collected from ISOLDE) [1] at CERN led to promising clinical trials over the
past 8 years carried out by C. Müller et al. [2, 3, 4, 5] Consequently, these trials have motivated
research into alternative production methods.
Table 2. The decay modes and most intense gamma transitions of the terbium isotopes used
in theragnostics and their medical purpose. Here, Eα is the energy of the emitted α particle,
Eβ is the energy of the emitted β particle, Eγ is the energy of the emitted γ-ray and Iγ is the










































The “quadruplet” of terbium isotopes (149Tb, 152Tb, 155Tb and 161Tb) proposed for
theragnostic use possess the suitable properties for medical isotopes. These isotopes can be
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used for all four aspects of nuclear medicine, α therapy, PET imaging, SPECT imaging and
β− therapy, respectively. Table 2 lists the half-lifes and energies of the emitted radiation from
each isotope. Both the half-lifes and emitted energies for each isotope are suitable for medical
purposes.
Looking at table 2, the terbium isotopes can be paired according to their half-lifes. Both the
149Tb and 152Tb have similar half-lifes of hours and 155Tb and 161Tb have similar half-lifes of
days. The similar half-lifes of these pairs means that each pair can be used together to perform
a more accurate form of theragnositcs for patient dose calculations.
Medical studies carried out by C. Muller, et al [2, 3, 4, 5] have provided the evidence required
to further the investment into terbium production techniques. Their studies suggest that all
four of the terbium isotopes would perform well for each of their designed functions. In addition
to this, there is strong evidence [5] that, for example, in the case of prostate cancer 161Tb will
out perform 177Lu because 161Tb emits a β− with a lower energy and thus has shorter range in
tissue than 177Lu so can target a more localised region.
2. Production
The MC40 cyclotron at the University of Birmingham is capable of accelerating proton and
alpha particles up to 40 MeV and 3He nuclei and deuteron particles can also be accelerated
for isotope production. With these capabilities it is possible to produce 152 Tb and 155Tb and
potentially 149 Tb and 161Tb [1].
The initial research focus was the production of the diagnostic imaging isotopes. The cross-
section of interaction depends on energy. By varying the energy of the proton or alpha beam
incident on the target the ratios of products produced changed. In order to create Tb isotopes,
targets of either gadolinium or europium were used. Terbium isotopes can then be separated
from the irradiate target using radio-chemical techniques being developed and NPL (National
Physics Laboratory) [6].
For initial tests natural europium and gadolinium targets were used to identify which terbium
isotopes could be produced using the MC40 cyclotron.
2.1. Europium target
The reaction mechanism for the production of 152Tb and 155Tb using and alpha beam on an
natural europium target is as follows,
151Eu(α, 3n)152Tb
153Eu(α, 2n)155Tb
Initial investigations were done by looking at the PACE4 (Projection Angular-momentum
Couples Evaporation Monte Carlo code) [7, 8] cross-section calculations for the interaction of
alpha on a natural europium target (see figure 3(b)). The alpha beam energy was chosen
by selecting the energy where the cross-section was a maximum for 152Tb production. The
irradiated Eu target was then place in front of a HPGe (High Purity Germanium) detector to
identify products made using the emitted gammas. A small section of the gamma spectrum
collected is shown in figure 4. Looking at this section alone, it can be observed that 154Tb and
153Tb were identified but more importantly 152Tb in the ground state and excited isomer state
were also identified. The isomeric state has a half life of 4 minutes compared to 17.5hrs for the
ground state. Thus when gamma spectra were collected an hour later the purely isomeric 152Tb
states were no longer visible.
Although PACE4 was used for the initial investigation, the code does not differentiate between
different isomers of terbium. An alternative code, TALYS (nuclear reaction code) [9] can
differentiate between isomeric states. Comparing the PACE4 and TALYS cross-section (see
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Figure 3. Cross-sections of interaction vs. energy of alpha beam on an natural Eu target
(a)TALYS calculation (b)PACE4 calculation
figure 3(a)) there is a discrepancy between which alpha energy will produce the maximum cross-
section for 152Tb production. TALYS predicts a maximum cross-section at 34-36 MeV and
PACE4 at 40 MeV. In the energy region for the initial production, TALYS predicts a much
higher cross-section for the production of 153Tb compared to PACE4. This was reflected in
the gamma spectra data collected in figure 4 which displays the presence of 153Tb. Therefore,
for future investigation TALYS was used to calculate cross-sections to predict suitable beam
energies.
An investigation to measure the cross-section of interaction for the production of terbium
using an alpha beam incident on a europium target has begun. Preliminary results are currently
being analysed.
Figure 4. Calibrated section between 125 keV and 425 keV of the irradiated natural Eu foil
gamma spectra, labelled with identified gamma energies and isotopes responsible for energy
peaks
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To identify which terbium isotopes could be produced using a proton beam incident on a
gadolinium target, a natural gadolinium target was used. There are seven natural isotopes
of gadolinium compared to the two of europium. This increases the complexity of production
when comparing cross-section of interaction. The energy of the proton beam was selected using
TALYS cross-section calculations. The energy select was to ideally produce a high yield of 155Tb.
A preliminary analysis of the gamma spectra collected of the target (see figure 5) revealed that
155Tb was produced. The quantity of 155Tb produced and the identification of the other isotopes
present require further study.
Figure 5. Preliminary identification of 155Tb in an irradiated natural Gd foil
Summary
This preliminary study proved that the 152Tb isotope can successfully be produced at the MC40
cyclotron using an alpha beam on a europium target, and the 155Tb isotope could also be
produced using a proton beam on a gadolinium target. The cross-section for the the production
of terbium in each of these cases will be calculated from the spectra collected and compared to
the predicted cross-section made by PACE4, TALYS and EMPIRE [10].
The optimal beam energy for the production of each isotope will then be determined from
the cross-sections. Enriched targets will be used to gain a higher yield of the desired isotope
and reduce other terbium isotope contaminants which can not be removed by radio-chemical
separation at NPL.
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